IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-35133-4.html
   My bibliography  Save this article

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

Author

Listed:
  • Lingfang Xia

    (Fudan University Shanghai Cancer Center)

  • Qi Zhou

    (Affiliated Tumor Hospital of Chongqing University)

  • Yunong Gao

    (Beijing Cancer Hospital)

  • Wenjing Hu

    (Nanjing Drum Tower Hospital)

  • Ge Lou

    (Affiliated Tumor Hospital of Harbin Medical University)

  • Hong Sun

    (Obstetrics & Gynecology Hospital of Fudan University)

  • Jianqing Zhu

    (Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital))

  • Jin Shu

    (Affiliated Tumor Hospital of Chongqing University)

  • Xianfeng Zhou

    (Jiangsu Hengrui Pharmaceuticals Co., Ltd.)

  • Rong Sun

    (Jiangsu Hengrui Pharmaceuticals Co., Ltd.)

  • Xiaohua Wu

    (Fudan University Shanghai Cancer Center)

Abstract

This phase 2 study assesses the efficacy and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (anti-angiogenic agent) in women with pretreated recurrent or metastatic cervical cancer (ClinicalTrials.gov NCT03827837). Patients with histologically or cytologically confirmed cervical squamous cell carcinoma experiencing relapse or progression during or after 1–2 lines of systemic therapy for recurrent or metastatic disease are enrolled. Eligible patients receive camrelizumab 200 mg intravenously on day 1 of each 3-week cycle plus famitinib 20 mg orally once daily. The primary endpoint is the objective response rate. Secondary endpoints are duration of response, disease control rate, time to response, progression-free survival, overall survival, and safety. The trial has met pre-specified endpoint. Thirty-three patients are enrolled; median follow-up lasts for 13.6 months (interquartile range: 10.0–23.6). Objective responses are observed in 13 (39.4%, 95% confidence interval [CI]: 22.9–57.9) patients; the 12-month duration of response rate is 74.1% (95% CI: 39.1–90.9). Median progression-free survival is 10.3 months (95% CI: 3.5–not reached) and the 12-month overall survival rate is 77.7% (95% CI: 58.9–88.7). All patients experience treatment-related adverse events; grade ≥3 events occur in 26 (78.8%) patients. Treatment-related serious adverse events and deaths are observed in 9 (27.3%) and 2 (6.1%) patients, respectively. Camrelizumab plus famitinib shows promising antitumor activity with a manageable and tolerable safety profile in patients with pretreated recurrent or metastatic cervical squamous cell carcinoma. This combination may represent a treatment option for this population.

Suggested Citation

  • Lingfang Xia & Qi Zhou & Yunong Gao & Wenjing Hu & Ge Lou & Hong Sun & Jianqing Zhu & Jin Shu & Xianfeng Zhou & Rong Sun & Xiaohua Wu, 2022. "A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-35133-4
    DOI: 10.1038/s41467-022-35133-4
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-35133-4
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-35133-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Yong Lin & Weichung J. Shih, 2004. "Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials," Biometrics, The International Biometric Society, vol. 60(2), pages 482-490, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Sambucini, Valeria, 2019. "Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials," Computational Statistics & Data Analysis, Elsevier, vol. 132(C), pages 18-30.
    2. Cornelia U. Kunz & Meinhard Kieser, 2011. "Simon's minimax and optimal and Jung's admissible two-stage designs with or without curtailment," Stata Journal, StataCorp LP, vol. 11(2), pages 240-254, June.
    3. Stefan Englert & Meinhard Kieser, 2012. "Improving the Flexibility and Efficiency of Phase II Designs for Oncology Trials," Biometrics, The International Biometric Society, vol. 68(3), pages 886-892, September.
    4. Kim, Seongho & Wong, Weng Kee, 2022. "Spatial two-stage designs for phase II clinical trials," Computational Statistics & Data Analysis, Elsevier, vol. 169(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-35133-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.